Get startedLog in
    Picture of Lansen Pharmaceutical Holdings logo

    503 — Lansen Pharmaceutical Holdings Cashflow Statement

    0.000.00%
    hk flag iconLast trade - 00:00
    HealthcareHighly SpeculativeSmall Cap
    Balance sheetIncome statementCashflow
    Subscribe to view all data

    Annual cashflow statement for Lansen Pharmaceutical Holdings, fiscal year end - December 31st, USD millions except per share, conversion factor applied.

    2018
    December 31st
    2019
    December 31st
    2020
    December 31st
    2021
    December 31st
    2022
    December 31st
    Period Length:12 M12 M12 M12 M12 M
    Source:ARSARSARSARSARS
    Standards:
    IFRS
    IFRS
    IFRS
    IFRS
    IFRS
    Status:FinalFinalFinalFinalFinal
    Net Income/Starting Line2.0918.691.42.49.91
    Depreciation
    Amortisation
    Non-Cash Items2.58-10.5-77.66.392.96
    Unusual Items
    Equity in Net Earnings/Losses
    Other Non-Cash Items
    Changes in Working Capital-5.79-5.172.88-2.652.6
    Change in Accounts Receivable
    Change in Inventories
    Change in Payable / Accrued Expenses
    Change in Other Liabilities
    Other Operating Cash Flow
    Cash from Operating Activities2.566.9219.79.0218.1
    Capital Expenditures-4.92-3.52-2.8-1.71-1.52
    Purchase of Fixed Assets
    Purchase / Acquisition of Intangibles
    Other Investing Cash Flow Items18.236.17731.95.35
    Acquisition of Business
    Sale of Business
    Sale of Fixed Assets
    Sale/Maturity of Investment
    Purchase of Investments
    Other Investing Cash Flow
    Cash from Investing Activities13.232.674.230.23.82
    Total Cash Dividends Paid
    Net Issuance / Retirement of Stock
    Net Issuance / Retirement of Debt
    Cash from Financing Activities-12.7-30.6-31.8-90.4-0.932
    Foreign Exchange Effects
    Beginning Cash Balance
    Ending Cash Balance
    Net Change in Cash2.678.863-50.918.8